title: Induction of cytotoxic T lymphocytes against ovarian cancer-initiating cells.
abstract: The majority of patients with stage III/IV ovarian carcinoma that respond initially to standard therapies ultimately undergo relapse due to the survival of small populations of cells with tumor-initiating potential. These ovarian cancer (OVCA)-initiating cells (OCIC) are sometimes called cancer stem cells (CSC) because they express stem cell markers, and can survive conventional therapies such as chemotherapy, which usually target rapidly replicating tumor cells, and give rise to recurrent tumors that are more chemo-resistant and more aggressive. Thus, it would be desirable to develop a therapy that could selectively target OCIC and be used to complement the conventional therapies. In this study, we isolated a subset of OVCA cells with a CD44(+)  phenotype in samples from patients with OVCA that possess CSC properties including the formation of spheroids in culture, self-renewal and the ability to be engrafted in immune-compromised mice. We next explored the use of immunotherapy using fusions of dendritic cells and OCIC to specifically target the OCIC subpopulations. Fusion cells (FCs) prepared in this way activated T cells to express elevated levels of IFN-γ with enhanced killing of CD44(+)  OVCA cells. We envision a combined approach where conventional therapies such as chemotherapy kill the bulk of tumor cells, whereas OCIC-reactive cytotoxic T lymphocytes target the resistant OCIC fraction. A combined therapy such as this may represent a promising approach for the treatment of OVCA.
authors.affiliation: Department of Medicine, Boston University School of Medicine, Boston, MA 02118,USA.
authors.forename: Desheng
authors.initials: D
authors.lastname: Weng
authors.forename: Baizheng
authors.initials: B
authors.lastname: Song
authors.forename: John
authors.initials: J
authors.lastname: Durfee
authors.forename: Valerie
authors.initials: V
authors.lastname: Sugiyama
authors.forename: Zhengrong
authors.initials: Z
authors.lastname: Wu
authors.forename: Shigeo
authors.initials: S
authors.lastname: Koido
authors.forename: Stuart K
authors.initials: SK
authors.lastname: Calderwood
authors.forename: Jianlin
authors.initials: J
authors.lastname: Gong
mesh_terms: D000818:Animals; D019496:Cancer Vaccines / Q000627:therapeutic use*; D002459:Cell Fusion; D003713:Dendritic Cells / Q000276:immunology*; D005260:Female; D006801:Humans; D018960:Hyaluronan Receptors / Q000378:metabolism; D007371:Interferon-gamma / Q000378:metabolism; D008213:Lymphocyte Activation; D051379:Mice; D008819:Mice, Nude; D014411:Neoplastic Stem Cells / Q000276:immunology*; D010051:Ovarian Neoplasms / Q000628:therapy*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*
chemical_list: D019496:Cancer Vaccines; D018960:Hyaluronan Receptors; D007371:Interferon-gamma